341 related articles for article (PubMed ID: 30003863)
1. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
2. Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion.
Karami Z; Saghatchi Zanjani MR; Nasihatsheno N; Hamidi M
J Biomed Mater Res B Appl Biomater; 2020 Apr; 108(3):717-728. PubMed ID: 31187938
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
5. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
6. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
7. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
8. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
9. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Ige PP; Baria RK; Gattani SG
Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
[TBL] [Abstract][Full Text] [Related]
10. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
11. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
12. Nanoemulsion: for improved oral delivery of repaglinide.
Akhtar J; Siddiqui HH; Fareed S; Badruddeen ; Khalid M; Aqil M
Drug Deliv; 2016 Jul; 23(6):2026-34. PubMed ID: 27187792
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Jain S; Saraf S
J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
[TBL] [Abstract][Full Text] [Related]
14. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
15. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
Parmar K; Oza K
AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
[TBL] [Abstract][Full Text] [Related]
17. Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.
Rahim H; Sadiq A; Ullah R; Bari A; Amin F; Farooq U; Ullah Jan N; Mahmood HM
Int J Nanomedicine; 2020; 15():8999-9009. PubMed ID: 33235448
[TBL] [Abstract][Full Text] [Related]
18. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
20. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
